| Name | Title | Contact Details |
|---|
VNA is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sigvaris Inc is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adamas Pharmaceuticals, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Emeryville, CA. To find more information about Adamas Pharmaceuticals, Inc., please visit www.adamaspharma.com
As a non-profit business league, we`re funded by the healthcare industry to make the system work better for everyone. We do this work because we envision a future where providers can focus on delivering care. Health plans can focus on serving their customers. Purchasers can feel confident they`re getting the most value for their money. And where patients can ultimately get the best possible care at an affordable price. What brings us together at IHA is our passion to create a system where patients always receive the best possible care. We leave our egos at the door. We embrace the tough conversations. And we never lose sight of driving results. United by our values of Collaboration, Candor and Impact, our dedicated team works every day in support of high-quality, efficient care for all Californians. Our 40-member board of directors includes leaders from health plans, physician organizations, hospitals, health systems, purchasers, consumer groups, universities, and pharmaceutical and technology companies.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.